Oncogene amplification and overexpression of oncoproteins in thyroid papillary cancer.

BACKGROUND Several oncogene aberrations have been found in papillary thyroid cancer, the incidence of which has increased after the accident in Chernoby. The occurrence and prognostic significance of these aberrations may have importance in therapeutic strategies. MATERIALS AND METHODS Tumour tissues from 24 patients were investigated by Dot-blot DNA hybridisation for c-myc, Ha-ras amplification and p53 deletion, and by immunohistochemical method for cyclin D1, p53 and p21 overexpression. RESULTS Overexpression of p53 protein was detected in 66.6%, with p21 expression (25%) without any influence on tumour phenotype. Cyclin D1 overexpression was found in 50% to be associated with p21, in inverse relation to Iymphocytic infiltration. Overexpression of estrogen receptor was shown in 4 cyclin D1-positive samples (17%). CONCLUSION Our results suggest that cyclin D1 overexpression is associated with poor prognosis. The co-expression of cyclin D1 and p21 causes a CDK-independent, estrogen receptor-mediated effect of the cyclin D1 also described in breast cancer.

[1]  M. Zou,et al.  Thyroid carcinoma is characterized by genomic instability: evidence from p53 mutations. , 2001, Molecular genetics and metabolism.

[2]  G. Fontanini,et al.  Cyclin D1 overexpression in thyroid carcinomas: relation with clinico-pathological parameters, retinoblastoma gene product, and Ki67 labeling index. , 2000, Thyroid : official journal of the American Thyroid Association.

[3]  F. Puglisi,et al.  Expression of Pax-8, p53 and bcl-2 in human benign and malignant thyroid diseases. , 2000, Anticancer research.

[4]  R. Bernards.  CDK-independent activities of D type cyclins. , 1999, Biochimica et biophysica acta.

[5]  K. Franssila,et al.  DNA copy number changes in thyroid carcinoma. , 1999, The American journal of pathology.

[6]  L. Donehower,et al.  Heterozygosity of p21WAF1/CIP1 enhances tumor cell proliferation and cyclin D1-associated kinase activity in a murine mammary cancer model. , 1999, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[7]  F. Wyllie,et al.  Human thyroid cancer cells as a source of iso-genic, iso-phenotypic cell lines with or without functional p53 , 1999, British Journal of Cancer.

[8]  C. Muro-Cacho,et al.  Cyclin D1 Expression as a Prognostic Parameter in Papillary Carcinoma of the Thyroid , 1999, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[9]  L. Donehower,et al.  Heterozygosity of p 21 WAF 1 / CIP 1 Enhances Tumor Cell Proliferation and Cyclin D 1-associated Kinase Activity in a Murine Mammary Cancer Model 1 , 1999 .

[10]  S. Wang,et al.  The role of cell cycle regulatory proteins, cyclin D1, cyclin E, and p27 in thyroid carcinogenesis. , 1998, Human pathology.

[11]  D. Lazzereschi,et al.  Cyclin D1 and cyclin E expression in malignant thyroid cells and in human thyroid carcinomas , 1998, International journal of cancer.

[12]  R. Bernards,et al.  CDK-Independent Activation of Estrogen Receptor by Cyclin D1 , 1997, Cell.

[13]  G. Balázs,et al.  Veränderungen der epidemiologischen Parameter von SD-Erkrankungen in Ostungarn zehn Jahre nach Tschernobyl , 1997 .

[14]  M. Monden,et al.  Expression of p21 (WAF1/CIP1) protein in clinical thyroid tissues. , 1996, British Journal of Cancer.

[15]  O. Ozaki,et al.  Papillary Carcinoma of the Thyroid: Tall-cell Variant with Extensive Lymphocyte Infiltration , 1996 .

[16]  L. Hsieh,et al.  p53 gene mutation in thyroid carcinoma. , 1996, Cancer letters.

[17]  M. Kásler,et al.  Malignus pajzsmirigytumorok Magyarországon: morbiditás és mortalitás. , 1996 .

[18]  F. Matsuzuka,et al.  The correlation between papillary thyroid carcinoma and lymphocytic infiltration in the thyroid gland. , 1995, The Journal of clinical endocrinology and metabolism.

[19]  P. Soares,et al.  Recent advances in cytometry, cytogenetics and molecular genetics of thyroid tumours and tumour-like lesions. , 1995, Pathology, research and practice.

[20]  M. Zou,et al.  Molecular basis of thyroid cancer. , 1994, Endocrine reviews.

[21]  T. Oyama,et al.  Stepwise participation of p53 gene mutation during dedifferentiation of human thyroid carcinomas. , 1994, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[22]  Y. Monden,et al.  Immunohistochemical study of estrogen receptors and the responsiveness to estrogen in papillary thyroid carcinoma , 1993, Cancer.

[23]  T. Oyama,et al.  Overexpression of p53 as a Possible Prognostic Factor in Human Thyroid Carcinoma , 1993, The American journal of surgical pathology.

[24]  N. Konishi,et al.  Immunohistochemical analysis of estrogen receptors in 313 paraffin section cases of human thyroid tissue. , 1993, Oncology.

[25]  E. Strong,et al.  Estrogen and progesterone receptor content in human thyroid disease. , 1993, American journal of clinical pathology.

[26]  M. Romano,et al.  Relationship between the level of c-myc mRNA and histologic aggressiveness in thyroid tumors. , 1993, Hormone research.

[27]  J. Fagin,et al.  High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. , 1993, The Journal of clinical investigation.

[28]  Y. Yang.  [Expression, amplification and rearrangement of c-myc gene in human thyroid carcinoma]. , 1991, Zhonghua yi xue za zhi.

[29]  P. Frossard,et al.  BanII and ScaI RFLPs at the human p53 gene locus. , 1988, Nucleic acids research.

[30]  B. Vogelstein,et al.  Purification of DNA from formaldehyde fixed and paraffin embedded human tissue. , 1985, Biochemical and biophysical research communications.

[31]  C. Croce,et al.  Differential expression of the normal and of the translocated human c-myc oncogenes in B cells. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[32]  R. Weinberg,et al.  Characterization of a human colon/lung carcinoma oncogene , 1983, Nature.